Amneal Intermediate Inc
NASDAQ:AMRX
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.36
8.83
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one AMRX stock under the Base Case scenario is 14.64 USD. Compared to the current market price of 8.46 USD, Amneal Intermediate Inc is Undervalued by 42%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Amneal Intermediate Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for AMRX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Amneal Intermediate Inc
Balance Sheet Decomposition
Amneal Intermediate Inc
Current Assets | 1.4B |
Cash & Short-Term Investments | 91.5m |
Receivables | 645.7m |
Other Current Assets | 640.7m |
Non-Current Assets | 2.1B |
PP&E | 550.1m |
Intangibles | 1.5B |
Other Non-Current Assets | 55.5m |
Current Liabilities | 846.6m |
Accounts Payable | 143.6m |
Accrued Liabilities | 403.1m |
Short-Term Debt | 179m |
Other Current Liabilities | 120.9m |
Non-Current Liabilities | 2.6B |
Long-Term Debt | 2.5B |
Other Non-Current Liabilities | 120.2m |
Earnings Waterfall
Amneal Intermediate Inc
Revenue
|
2.4B
USD
|
Cost of Revenue
|
-1.5B
USD
|
Gross Profit
|
856.7m
USD
|
Operating Expenses
|
-581.8m
USD
|
Operating Income
|
274.8m
USD
|
Other Expenses
|
-358.8m
USD
|
Net Income
|
-84m
USD
|
Free Cash Flow Analysis
Amneal Intermediate Inc
USD | |
Free Cash Flow | USD |
Amneal Pharmaceuticals reported strong growth in Q2 2024, with revenues rising 17% to $702 million, driven by generics and specialty medicines. The company’s 2024 revenue guidance was increased to $2.7 - $2.8 billion, reflecting a 13% to 17% year-over-year growth. Amneal is also launching CREXONT for Parkinson's disease, expected to contribute $300-$500 million in U.S. peak sales, aiding their specialty segment to exceed $500 million in revenue by 2027. Additionally, the company continues to expand its biosimilars portfolio, anticipating over $125 million in 2024 revenue from this segment.
What is Earnings Call?
AMRX Profitability Score
Profitability Due Diligence
Amneal Intermediate Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
Score
Amneal Intermediate Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
AMRX Solvency Score
Solvency Due Diligence
Amneal Intermediate Inc's solvency score is 22/100. The higher the solvency score, the more solvent the company is.
Score
Amneal Intermediate Inc's solvency score is 22/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AMRX Price Targets Summary
Amneal Intermediate Inc
According to Wall Street analysts, the average 1-year price target for AMRX is 9.86 USD with a low forecast of 9.09 USD and a high forecast of 10.5 USD.
Dividends
Current shareholder yield for AMRX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
AMRX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 7,600 full-time employees. The company went IPO on 2009-03-16. The firm specializes in developing, manufacturing, marketing and distributing generic, injectables, biosimilars and branded specialty pharmaceutical products. Its segments include Generics, Specialty, and AvKARE. Its Generics segment includes approximately 250 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system (CNS) disorders, including Parkinson’s disease, and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies.
Contact
IPO
Employees
Officers
The intrinsic value of one AMRX stock under the Base Case scenario is 14.64 USD.
Compared to the current market price of 8.46 USD, Amneal Intermediate Inc is Undervalued by 42%.